Stephen Mandel Argenx Se Transaction History

Lone Pine Capital LLC

  • $12.9 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$257.11 - $319.92 $140 Million - $175 Million
-546,259 Closed
0 $0
Q1 2021

May 18, 2021
BUY
$268.3 - $380.31 $2.68 Million - $3.8 Million
10,000 Added 1.86%
546,259 $150 Million
Q4 2020

Feb 16, 2021
BUY
$248.13 - $308.36 $133 Million - $165 Million
536,259 New
536,259 $158 Million

Others Institutions Holding ARGX

# of Institutions
400
Shares Held
30.9M
Call Options Held
376K
Put Options Held
489K
View Full List

About ARGENX SE

ARGX Quotes by TradingView
  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track Stephen Mandel's Portfolio

Track Stephen Mandel Portfolio

Follow Stephen Mandel (Lone Pine Capital LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lone Pine Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lone Pine Capital LLC and Stephen Mandel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email